CA3064363C - Non-small cell lung cancer biomarkers and uses thereof - Google Patents
Non-small cell lung cancer biomarkers and uses thereof Download PDFInfo
- Publication number
- CA3064363C CA3064363C CA3064363A CA3064363A CA3064363C CA 3064363 C CA3064363 C CA 3064363C CA 3064363 A CA3064363 A CA 3064363A CA 3064363 A CA3064363 A CA 3064363A CA 3064363 C CA3064363 C CA 3064363C
- Authority
- CA
- Canada
- Prior art keywords
- biomarkers
- biomarker
- individual
- nsclc
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 259
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 259
- 239000000107 tumor biomarker Substances 0.000 title description 18
- 239000000090 biomarker Substances 0.000 claims abstract description 711
- 238000000034 method Methods 0.000 claims abstract description 328
- 239000012472 biological sample Substances 0.000 claims abstract description 114
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 56
- 108090000855 Matrilysin Proteins 0.000 claims abstract description 6
- 108010074051 C-Reactive Protein Proteins 0.000 claims abstract 6
- 102100032752 C-reactive protein Human genes 0.000 claims abstract 6
- 102000004318 Matrilysin Human genes 0.000 claims abstract 5
- 108091023037 Aptamer Proteins 0.000 claims description 144
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 102000004169 proteins and genes Human genes 0.000 claims description 76
- 210000001519 tissue Anatomy 0.000 claims description 62
- 238000003556 assay Methods 0.000 claims description 53
- 230000002685 pulmonary effect Effects 0.000 claims description 24
- 210000004072 lung Anatomy 0.000 claims description 23
- 238000012216 screening Methods 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 13
- 210000002381 plasma Anatomy 0.000 claims description 10
- 101001013520 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP7 Proteins 0.000 claims 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 140
- 201000011510 cancer Diseases 0.000 abstract description 117
- 238000001514 detection method Methods 0.000 abstract description 56
- 208000020816 lung neoplasm Diseases 0.000 abstract description 35
- 201000005202 lung cancer Diseases 0.000 abstract description 30
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 29
- 238000003745 diagnosis Methods 0.000 abstract description 27
- 102100030417 Matrilysin Human genes 0.000 description 197
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 196
- 101000829705 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) Thermosome subunit Proteins 0.000 description 160
- 239000013625 clathrin-independent carrier Substances 0.000 description 160
- 239000000523 sample Substances 0.000 description 154
- 102100029932 Syntaxin-1A Human genes 0.000 description 140
- 101000585070 Homo sapiens Syntaxin-1A Proteins 0.000 description 131
- 102100034667 Chloride intracellular channel protein 1 Human genes 0.000 description 120
- 101000946430 Homo sapiens Chloride intracellular channel protein 1 Proteins 0.000 description 120
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 118
- 101000979623 Homo sapiens Nucleoside diphosphate kinase B Proteins 0.000 description 117
- 102100023258 Nucleoside diphosphate kinase B Human genes 0.000 description 117
- 201000010099 disease Diseases 0.000 description 117
- 102100028443 Aflatoxin B1 aldehyde reductase member 2 Human genes 0.000 description 86
- 108010078976 aflatoxin B1 aldehyde reductase Proteins 0.000 description 86
- 239000003550 marker Substances 0.000 description 75
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 67
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 67
- 238000012360 testing method Methods 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 62
- 230000014509 gene expression Effects 0.000 description 52
- 230000008569 process Effects 0.000 description 50
- 238000011282 treatment Methods 0.000 description 47
- 102100027832 14-3-3 protein gamma Human genes 0.000 description 45
- 101000723517 Homo sapiens 14-3-3 protein gamma Proteins 0.000 description 45
- 230000000875 corresponding effect Effects 0.000 description 40
- 150000007523 nucleic acids Chemical class 0.000 description 37
- 239000000243 solution Substances 0.000 description 37
- 102100024326 Contactin-1 Human genes 0.000 description 36
- 101000909520 Homo sapiens Contactin-1 Proteins 0.000 description 36
- 238000002591 computed tomography Methods 0.000 description 36
- 238000002790 cross-validation Methods 0.000 description 36
- 102000039446 nucleic acids Human genes 0.000 description 36
- 108020004707 nucleic acids Proteins 0.000 description 36
- 239000007787 solid Substances 0.000 description 35
- 238000004590 computer program Methods 0.000 description 34
- 230000035945 sensitivity Effects 0.000 description 34
- 102100025440 BMP-binding endothelial regulator protein Human genes 0.000 description 31
- 101000934632 Homo sapiens BMP-binding endothelial regulator protein Proteins 0.000 description 31
- 230000006870 function Effects 0.000 description 27
- 238000003384 imaging method Methods 0.000 description 27
- 238000012549 training Methods 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 101000983170 Homo sapiens Proliferation-associated protein 2G4 Proteins 0.000 description 25
- 206010054107 Nodule Diseases 0.000 description 25
- 229920001213 Polysorbate 20 Polymers 0.000 description 25
- 102100026899 Proliferation-associated protein 2G4 Human genes 0.000 description 25
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 25
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 24
- 238000010186 staining Methods 0.000 description 24
- 239000012491 analyte Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 239000011324 bead Substances 0.000 description 22
- 102000004152 Bone morphogenetic protein 1 Human genes 0.000 description 21
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 21
- 101001017855 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 3 Proteins 0.000 description 21
- 102100033284 Leucine-rich repeats and immunoglobulin-like domains protein 3 Human genes 0.000 description 21
- 238000013459 approach Methods 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 239000002609 medium Substances 0.000 description 19
- 238000012163 sequencing technique Methods 0.000 description 19
- 238000002405 diagnostic procedure Methods 0.000 description 18
- 238000009826 distribution Methods 0.000 description 18
- 238000012545 processing Methods 0.000 description 18
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 17
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 17
- -1 methods Substances 0.000 description 17
- 238000001356 surgical procedure Methods 0.000 description 17
- 230000001419 dependent effect Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000004422 calculation algorithm Methods 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 238000009739 binding Methods 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 238000004949 mass spectrometry Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 13
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 12
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 description 12
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- 102100032765 Chordin-like protein 1 Human genes 0.000 description 11
- 101000941971 Homo sapiens Chordin-like protein 1 Proteins 0.000 description 11
- 206010056342 Pulmonary mass Diseases 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 11
- 229960002685 biotin Drugs 0.000 description 11
- 239000011616 biotin Substances 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- IVCWGAIYDLMKAJ-UHFFFAOYSA-N [4-(1-decylpiperidine-3-carbonyl)piperazin-1-yl]-(1-decylpiperidin-3-yl)methanone Chemical compound C1N(CCCCCCCCCC)CCCC1C(=O)N1CCN(C(=O)C2CN(CCCCCCCCCC)CCC2)CC1 IVCWGAIYDLMKAJ-UHFFFAOYSA-N 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 108091070501 miRNA Proteins 0.000 description 10
- 239000003001 serine protease inhibitor Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 9
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002380 cytological effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 239000000834 fixative Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 8
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 8
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 8
- 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100025805 Cadherin-1 Human genes 0.000 description 7
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- 244000099147 Ananas comosus Species 0.000 description 6
- 235000007119 Ananas comosus Nutrition 0.000 description 6
- 101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 6
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 210000000621 bronchi Anatomy 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000005315 distribution function Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003828 vacuum filtration Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102100022299 All trans-polyprenyl-diphosphate synthase PDSS1 Human genes 0.000 description 5
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 5
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 5
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 102100034869 Plasma kallikrein Human genes 0.000 description 5
- 101100130647 Rattus norvegicus Mmp7 gene Proteins 0.000 description 5
- 108050000761 Serpin Proteins 0.000 description 5
- 102000008847 Serpin Human genes 0.000 description 5
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 238000002820 assay format Methods 0.000 description 5
- 230000008238 biochemical pathway Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000013170 computed tomography imaging Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000007637 random forest analysis Methods 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 4
- 101100194816 Caenorhabditis elegans rig-3 gene Proteins 0.000 description 4
- 102100024539 Chymase Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 4
- 101000909983 Homo sapiens Chymase Proteins 0.000 description 4
- 101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000008366 buffered solution Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000003748 differential diagnosis Methods 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 238000011503 in vivo imaging Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 210000004224 pleura Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 101100242304 Arabidopsis thaliana GCP1 gene Proteins 0.000 description 3
- 101100412054 Arabidopsis thaliana RD19B gene Proteins 0.000 description 3
- 208000005156 Dehydration Diseases 0.000 description 3
- 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000948258 Gila Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101000609413 Homo sapiens Inter-alpha-trypsin inhibitor heavy chain H4 Proteins 0.000 description 3
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 3
- 102100039457 Inter-alpha-trypsin inhibitor heavy chain H4 Human genes 0.000 description 3
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100180429 Mus musculus Klk1b3 gene Proteins 0.000 description 3
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 3
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 3
- 101150118301 RDL1 gene Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 101100288126 Rattus norvegicus Klk3 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 3
- 101150032817 TPI1 gene Proteins 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 238000001854 atmospheric pressure photoionisation mass spectrometry Methods 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- 238000013276 bronchoscopy Methods 0.000 description 3
- 238000013527 convolutional neural network Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000011223 gene expression profiling Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000007885 magnetic separation Methods 0.000 description 3
- 239000006148 magnetic separator Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007837 multiplex assay Methods 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 238000011176 pooling Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000013179 statistical model Methods 0.000 description 3
- 229940056501 technetium 99m Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 102000004899 14-3-3 Proteins Human genes 0.000 description 2
- 101710112812 14-3-3 protein Proteins 0.000 description 2
- 102100024682 14-3-3 protein eta Human genes 0.000 description 2
- 101150034533 ATIC gene Proteins 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010031480 Artificial Receptors Proteins 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 102100031006 Beta-Ala-His dipeptidase Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100025222 CD63 antigen Human genes 0.000 description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100037068 Cytoplasmic dynein 1 light intermediate chain 1 Human genes 0.000 description 2
- 101100161150 Danio rerio ywhag1 gene Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100035617 Heterogeneous nuclear ribonucleoprotein A/B Human genes 0.000 description 2
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 description 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 2
- 101000919694 Homo sapiens Beta-Ala-His dipeptidase Proteins 0.000 description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 2
- 101000940068 Homo sapiens Collagen alpha-1(XVIII) chain Proteins 0.000 description 2
- 101000954692 Homo sapiens Cytoplasmic dynein 1 light intermediate chain 1 Proteins 0.000 description 2
- 101000854036 Homo sapiens Heterogeneous nuclear ribonucleoprotein A/B Proteins 0.000 description 2
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 2
- 101000701440 Homo sapiens Stanniocalcin-1 Proteins 0.000 description 2
- 101000697800 Homo sapiens Syntaxin-4 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100037963 Importin-7 Human genes 0.000 description 2
- 101710125784 Importin-7 Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 101100141312 Mus musculus Ripk1 gene Proteins 0.000 description 2
- 102000009065 Netrin-1 Human genes 0.000 description 2
- 108010074223 Netrin-1 Proteins 0.000 description 2
- 101100526762 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rpl-28 gene Proteins 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 101710162447 Pectin lyase A Proteins 0.000 description 2
- 206010035603 Pleural mesothelioma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 102100027975 Syntaxin-4 Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- 101710194411 Triosephosphate isomerase 1 Proteins 0.000 description 2
- 101150083738 YWHAG gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000013103 analytical ultracentrifugation Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 238000013476 bayesian approach Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000007418 data mining Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 238000001001 laser micro-dissection Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- RKWPZPDLTYBKCL-RVZGXXANSA-N meproscillarin Chemical compound O[C@@H]1[C@H](O)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 RKWPZPDLTYBKCL-RVZGXXANSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001531 micro-dissection Methods 0.000 description 2
- 238000012821 model calculation Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 238000003203 nucleic acid sequencing method Methods 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KMXPHBJUGYLXDM-LSDHHAIUSA-N 1-[(7r,8s)-7-hydroxy-6,6-dimethyl-7,8-dihydropyrano[2,3-f][2,1,3]benzoxadiazol-8-yl]piperidin-2-one Chemical compound N1([C@H]2C3=CC4=NON=C4C=C3OC([C@@H]2O)(C)C)CCCCC1=O KMXPHBJUGYLXDM-LSDHHAIUSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 1
- YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical compound O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
- BPPVUXSMLBXYGG-UHFFFAOYSA-N 4-[3-(4,5-dihydro-1,2-oxazol-3-yl)-2-methyl-4-methylsulfonylbenzoyl]-2-methyl-1h-pyrazol-3-one Chemical compound CC1=C(C(=O)C=2C(N(C)NC=2)=O)C=CC(S(C)(=O)=O)=C1C1=NOCC1 BPPVUXSMLBXYGG-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 description 1
- 101150067539 AMBP gene Proteins 0.000 description 1
- 108010082072 ATP Synthetase Complexes Proteins 0.000 description 1
- 102000003736 ATP Synthetase Complexes Human genes 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- 102100028445 Aflatoxin B1 aldehyde reductase member 4 Human genes 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 101710093939 All trans-polyprenyl-diphosphate synthase PDSS1 Proteins 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 101100391241 Antheraea mylitta fpi-1 gene Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 101100407152 Arabidopsis thaliana PBL7 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101001099542 Aspergillus niger Pectin lyase A Proteins 0.000 description 1
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101150002885 Avil gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 101150061050 CIN1 gene Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100038180 Caenorhabditis briggsae rpb-1 gene Proteins 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 101100004286 Caenorhabditis elegans best-5 gene Proteins 0.000 description 1
- 101100508408 Caenorhabditis elegans ifa-3 gene Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100026622 Cartilage intermediate layer protein 1 Human genes 0.000 description 1
- 241000040710 Chela Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001091551 Clio Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 101100022323 Drosophila melanogaster Marf gene Proteins 0.000 description 1
- 101100061188 Drosophila melanogaster dila gene Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101100056296 Homo sapiens AKR7L gene Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000714525 Homo sapiens Carbonic anhydrase 6 Proteins 0.000 description 1
- 101000913767 Homo sapiens Cartilage intermediate layer protein 1 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 description 1
- 101100083571 Homo sapiens PLPPR3 gene Proteins 0.000 description 1
- 101000738966 Homo sapiens POU domain, class 6, transcription factor 1 Proteins 0.000 description 1
- 101001126084 Homo sapiens Piwi-like protein 2 Proteins 0.000 description 1
- 101001015936 Homo sapiens Probable rRNA-processing protein EBP2 Proteins 0.000 description 1
- 101000755620 Homo sapiens Protein RIC-3 Proteins 0.000 description 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101001094531 Homo sapiens Reticulon-4-interacting protein 1, mitochondrial Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000848014 Homo sapiens Trypsin-2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 102100024573 Macrophage-capping protein Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 101710201354 Metallothionein A Proteins 0.000 description 1
- 101710094503 Metallothionein-1 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100162168 Mus musculus Adam1a gene Proteins 0.000 description 1
- 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 description 1
- 101100437772 Mus musculus Bmper gene Proteins 0.000 description 1
- 101100456970 Mus musculus Mfn2 gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000003921 N-acetyl-beta-D-galactosaminyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl group Chemical group 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 101150070935 NIA2 gene Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101100491995 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-1 gene Proteins 0.000 description 1
- 101100471181 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) crp-63 gene Proteins 0.000 description 1
- 101100225582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nip-1 gene Proteins 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 101100297537 Oryza sativa subsp. japonica PHP2 gene Proteins 0.000 description 1
- 101100150875 Oryza sativa subsp. japonica SUS1 gene Proteins 0.000 description 1
- 238000005052 Osteryoung square wave voltammetry Methods 0.000 description 1
- 229910019142 PO4 Chemical group 0.000 description 1
- 102100037483 POU domain, class 6, transcription factor 1 Human genes 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 102100030383 Phospholipid phosphatase-related protein type 3 Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102100029365 Piwi-like protein 2 Human genes 0.000 description 1
- 241000158500 Platanus racemosa Species 0.000 description 1
- 241000791420 Plica Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100032223 Probable rRNA-processing protein EBP2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100022368 Protein RIC-3 Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 241001632427 Radiola Species 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 101100322557 Rattus norvegicus Adam1 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
- 102100035121 Reticulon-4-interacting protein 1, mitochondrial Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 244000117054 Rungia klossii Species 0.000 description 1
- 235000002492 Rungia klossii Nutrition 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 101100123432 Schizosaccharomyces pombe (strain 972 / ATCC 24843) hap2 gene Proteins 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101100490407 Solanum tuberosum AC71 gene Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000013265 Syntaxin 1 Human genes 0.000 description 1
- 108010090618 Syntaxin 1 Proteins 0.000 description 1
- 108700012457 TACSTD2 Proteins 0.000 description 1
- 101710168651 Thioredoxin 1 Proteins 0.000 description 1
- 108091046915 Threose nucleic acid Proteins 0.000 description 1
- 102000007641 Trefoil Factors Human genes 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100034392 Trypsin-2 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 1
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AVVWPBAENSWJCB-DGPNFKTASA-N beta-D-galactofuranose Chemical compound OC[C@@H](O)[C@@H]1O[C@@H](O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-DGPNFKTASA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OMFRMAHOUUJSGP-IRHGGOMRSA-N bifenthrin Chemical compound C1=CC=C(C=2C=CC=CC=2)C(C)=C1COC(=O)[C@@H]1[C@H](\C=C(/Cl)C(F)(F)F)C1(C)C OMFRMAHOUUJSGP-IRHGGOMRSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003392 chemiluminescence resonance energy transfer Methods 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical class CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 101150113676 chr1 gene Proteins 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000011209 electrochromatography Methods 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 101150060566 galF gene Proteins 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZSDBFLMJVAGKOU-UHFFFAOYSA-N glycerol phenylbutyrate Chemical compound C=1C=CC=CC=1CCCC(=O)OCC(OC(=O)CCCC=1C=CC=CC=1)COC(=O)CCCC1=CC=CC=C1 ZSDBFLMJVAGKOU-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 101150017578 hrdl-1 gene Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091031054 miR-37 stem-loop Proteins 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000011512 multiplexed immunoassay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000382 optic material Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 229940086255 perform Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000010384 proximity ligation assay Methods 0.000 description 1
- 150000003230 pyrimidines Chemical group 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000016515 regulation of signal transduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000001040 scanning transmission X-ray microscopy Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 108010051423 streptavidin-agarose Proteins 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000010897 surface acoustic wave method Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000001776 time-resolved fluorescence quenching Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3064363A CA3064363C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2847188A CA2847188C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
PCT/US2011/057499 WO2013062515A2 (en) | 2011-10-24 | 2011-10-24 | Lung cancer biomarkers and uses thereof |
CA3064363A CA3064363C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2847188A Division CA2847188C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3064363A1 CA3064363A1 (en) | 2013-05-02 |
CA3064363C true CA3064363C (en) | 2022-05-17 |
Family
ID=48168748
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3064363A Active CA3064363C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
CA2847188A Active CA2847188C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
CA3006793A Active CA3006793C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2847188A Active CA2847188C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
CA3006793A Active CA3006793C (en) | 2011-10-24 | 2011-10-24 | Non-small cell lung cancer biomarkers and uses thereof |
Country Status (15)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011274422B2 (en) | 2010-07-09 | 2016-02-11 | Somalogic Operating Co., Inc. | Lung cancer biomarkers and uses thereof |
WO2014179959A1 (en) * | 2013-05-09 | 2014-11-13 | The Procter & Gamble Company | Method and system for assessing health condition |
WO2016018963A1 (en) | 2014-07-30 | 2016-02-04 | President And Fellows Of Harvard College | Probe library construction |
CN104263723B (zh) * | 2014-09-15 | 2017-06-06 | 南京医科大学 | 一种与原发性肺癌辅助诊断相关的低频高外显性遗传标志物及其应用 |
WO2016094330A2 (en) * | 2014-12-08 | 2016-06-16 | 20/20 Genesystems, Inc | Methods and machine learning systems for predicting the liklihood or risk of having cancer |
KR102087373B1 (ko) * | 2015-09-11 | 2020-03-10 | 주식회사 압타머사이언스 | 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법 |
KR102086935B1 (ko) * | 2015-11-05 | 2020-03-09 | 비지아이 션전 | 폐 선암종을 검출하기 위한 생체마커 및 그의 사용 |
EP3430137A4 (en) * | 2016-03-18 | 2019-11-06 | Caris Science, Inc. | OLIGONUCLEOTIDE THONES AND USES THEREOF |
KR101853118B1 (ko) * | 2016-09-02 | 2018-04-30 | 주식회사 바이오인프라생명과학 | 피험체의 폐암 진단을 위한 복합 바이오마커군, 이를 이용하는 폐암 진단용 키트, 복합 바이오마커군의 정보를 이용하는 방법 및 이를 수행하는 컴퓨팅 시스템 |
EP4386761A3 (en) * | 2016-11-08 | 2024-09-04 | President and Fellows of Harvard College | Matrix imprinting and clearing |
JP7128196B2 (ja) * | 2017-03-01 | 2022-08-30 | エフ.ホフマン-ラ ロシュ アーゲー | 検体の存在に関する生体サンプルの分類のためのシステムおよび方法 |
WO2018218150A1 (en) | 2017-05-26 | 2018-11-29 | President And Fellows Of Harvard College | Systems and methods for high-throughput image-based screening |
CN109116023B (zh) * | 2018-06-14 | 2021-06-04 | 郑州大学第一附属医院 | 一种肺癌标志物抗-mmp12自身抗体及其应用 |
CN109470859A (zh) * | 2018-11-04 | 2019-03-15 | 华东医院 | 一种外泌体蛋白作为鉴别肺结节良恶性标志物及其应用 |
EP3671210A1 (en) * | 2018-12-21 | 2020-06-24 | Biosystems International KFT | Lung cancer protein epitomic biomarkers |
CN113711313A (zh) * | 2019-02-15 | 2021-11-26 | 佰欧迪塞克斯公司 | 用于识别手术后处于高复发风险的早期nsclc患者的预测性测试 |
CN110473167B (zh) * | 2019-07-09 | 2022-06-17 | 哈尔滨工程大学 | 一种基于深度学习的尿沉渣图像识别系统及方法 |
CN112892619B (zh) * | 2019-12-04 | 2022-07-15 | 香港城市大学深圳研究院 | 弧形边缘截面的pdms母模、微流控阀和芯片及其制备 |
KR102613772B1 (ko) * | 2021-02-02 | 2023-12-14 | 제노마인(주) | 폐암 혈액 바이오마커의 검출 방법 및 키트 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
DE602005024021D1 (de) * | 2004-08-10 | 2010-11-18 | Oncotherapy Science Inc | GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA |
JP2009502115A (ja) * | 2005-07-27 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | 小細胞肺癌の診断方法 |
US20080305962A1 (en) * | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
US8014957B2 (en) * | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
WO2008046911A2 (en) * | 2006-10-20 | 2008-04-24 | Exiqon A/S | Novel human micrornas associated with cancer |
GB0803192D0 (en) * | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
US10359425B2 (en) * | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
HRP20160127T1 (hr) * | 2008-09-09 | 2016-03-11 | Somalogic, Inc. | Biomarkeri raka pluä†a i njihove uporabe |
CA2743473C (en) | 2008-11-17 | 2022-06-14 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
US20110236903A1 (en) * | 2008-12-04 | 2011-09-29 | Mcclelland Michael | Materials and methods for determining diagnosis and prognosis of prostate cancer |
WO2011100472A1 (en) * | 2010-02-10 | 2011-08-18 | The Regents Of The University Of California | Salivary transcriptomic and proteomic biomarkers for breast cancer detection |
US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
-
2011
- 2011-10-24 CN CN201180074349.4A patent/CN103890586B/zh active Active
- 2011-10-24 SG SG11201400375SA patent/SG11201400375SA/en unknown
- 2011-10-24 NZ NZ621733A patent/NZ621733A/en not_active IP Right Cessation
- 2011-10-24 KR KR1020147013714A patent/KR101921945B1/ko active Active
- 2011-10-24 MX MX2014004860A patent/MX355416B/es active IP Right Grant
- 2011-10-24 EP EP11874668.4A patent/EP2771692B1/en active Active
- 2011-10-24 CA CA3064363A patent/CA3064363C/en active Active
- 2011-10-24 AU AU2011378427A patent/AU2011378427B8/en active Active
- 2011-10-24 CN CN201610457386.8A patent/CN106168624B/zh active Active
- 2011-10-24 JP JP2014538759A patent/JP5986638B2/ja active Active
- 2011-10-24 CA CA2847188A patent/CA2847188C/en active Active
- 2011-10-24 IN IN1787CHN2014 patent/IN2014CN01787A/en unknown
- 2011-10-24 WO PCT/US2011/057499 patent/WO2013062515A2/en not_active Application Discontinuation
- 2011-10-24 CA CA3006793A patent/CA3006793C/en active Active
- 2011-10-24 ES ES11874668.4T patent/ES2674318T3/es active Active
- 2011-10-24 BR BR112014006432A patent/BR112014006432B8/pt active IP Right Grant
-
2014
- 2014-02-26 ZA ZA2014/01476A patent/ZA201401476B/en unknown
- 2014-03-10 IL IL231426A patent/IL231426A/en active IP Right Grant
-
2017
- 2017-05-08 IL IL252163A patent/IL252163A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3064363C (en) | Non-small cell lung cancer biomarkers and uses thereof | |
US11041866B2 (en) | Pancreatic cancer biomarkers and uses thereof | |
AU2015249113B2 (en) | Lung cancer biomarkers and uses thereof | |
CA2809282C (en) | Mesothelioma biomarkers and uses thereof | |
US20120101002A1 (en) | Lung Cancer Biomarkers and Uses Thereof | |
US20120143805A1 (en) | Cancer Biomarkers and Uses Thereof | |
WO2011031344A1 (en) | Cancer biomarkers and uses thereof | |
WO2011043840A1 (en) | Cancer biomarkers and uses thereof | |
US20120165217A1 (en) | Cancer Biomarkers and Uses Thereof | |
WO2010042525A9 (en) | Ovarian cancer biomarkers and uses thereof | |
US20220065872A1 (en) | Lung Cancer Biomarkers and Uses Thereof | |
HK1196429B (en) | Lung cancer biomarkers and uses thereof | |
HK1196429A (en) | Lung cancer biomarkers and uses thereof | |
HK1153834B (en) | Lung cancer biomarkers and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20191211 |